Take­da, Abing­worth pro­vide a $100M bankroll for an up­start T cell play­er, build­ing in a buy­out op­tion

Over the past year Take­da has been rip­ping up its old glob­al R&D or­ga­ni­za­tion and cre­at­ing a new one, with a whole new set …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA